Dyne Therapeutics, Inc.
Biotechnology company developing muscle-targeted therapeutics for genetically driven neuromuscular diseases. Uses a modular delivery platform that combines an antibody fragment-based targeting moiety, a linker, and interchangeable therapeutic payloads (oligonucleotides and small molecules) to address diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). Operates preclinical and clinical-stage programs and maintains functions across analytical development, CMC/CMC documentation, clinical operations, and regulatory interactions.
Industries
Nr. of Employees
medium (51-250)
Dyne Therapeutics, Inc.
Patents
Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy
US-12752013-B2
View DetailsMuscle targeting complexes and uses thereof for treating myotonic dystrophy
US-12746290-B2
View DetailsAnti-transferrin receptor (TFR) antibody, encoding nucleic acid thereof and method of use thereof to deliver an oligonucleotide to a subject
US-12734246-B2
View DetailsMuscle targeting complexes and formulations for treating myotonic dystrophy
US-12697394-B2
View DetailsComplexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US-12662545-B2
View Details
Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy
US-12752013-B2
View DetailsMuscle targeting complexes and uses thereof for treating myotonic dystrophy
US-12746290-B2
View DetailsAnti-transferrin receptor (TFR) antibody, encoding nucleic acid thereof and method of use thereof to deliver an oligonucleotide to a subject
US-12734246-B2
View DetailsMuscle targeting complexes and formulations for treating myotonic dystrophy
US-12697394-B2
View DetailsComplexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US-12662545-B2
View DetailsProducts
Investigational muscle-targeted therapeutics (clinical-stage)
Investigational therapeutics using a modular Fab–linker–payload platform targeting genetically driven neuromuscular diseases, with clinical-stage programs focused on Duchenne muscular dystrophy and myotonic dystrophy type 1.
Preclinical development programs (FSHD, Pompe, additional DMD mutations)
Preclinical programs applying the modular delivery platform and oligonucleotide/small-molecule payloads to additional rare muscle disease targets.
Investigational muscle-targeted therapeutics (clinical-stage)
Investigational therapeutics using a modular Fab–linker–payload platform targeting genetically driven neuromuscular diseases, with clinical-stage programs focused on Duchenne muscular dystrophy and myotonic dystrophy type 1.
Preclinical development programs (FSHD, Pompe, additional DMD mutations)
Preclinical programs applying the modular delivery platform and oligonucleotide/small-molecule payloads to additional rare muscle disease targets.
Expertise Areas
- Clinical trial management
- Muscle-targeted delivery and targeting biology
- Oligonucleotide therapeutics development (ASO, PMO, siRNA)
- Analytical development and quality control
Key Technologies
- Antibody-fragment (Fab) targeting to transferrin receptor (TfR1)
- Linker chemistry for conjugation
- Antisense oligonucleotides (ASO)
- Phosphorodiamidate morpholino oligomers (PMO)
News & Updates
Press release reporting inducement grants under Nasdaq listing rules.
Press release announcing additional clinical data from a Phase 1/2 trial in DM1.
Press release reporting inducement grants under Nasdaq listing rules.
Press release announcing additional clinical data from a Phase 1/2 trial in DM1.